TLP
TARS icon

Tri Locum Partners’s Tarsus Pharmaceuticals TARS Stock Holding History

Tri Locum Partners’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.7M Buy
328,340
+75,752
+30% +$4.84M 2.54% 14
2026
Q1 		$17.7M Buy
+252,588
New +$17.6M 2.49% 14
2025
Q4 		– Sell
-119,260
Closed -$7.09M – 24
2025
Q3 		$7.09M Sell
119,260
-58,396
-33% -$2.87M 1.63% 16
2025
Q2 		$7.2M Buy
+177,656
New +$8M 2.18% 16

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Tri Locum Partners's TARS Position: Q2 2026 in Review

Tri Locum Partners increased its Tarsus Pharmaceuticals (TARS) stake by 30% in Q2 2026, buying an estimated $4.84M and bringing the position to 328,340 shares worth $20.7M. The position accounts for 2.54% of the portfolio, ranked #14.

Tri Locum Partners first reported a position in TARS in Q2 2025 and has held it in 4 quarters since. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Tri Locum Partners held 328,340 shares of Tarsus Pharmaceuticals worth $20.7M as of Q2 2026.
  • Tri Locum Partners bought 75,752 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $4.84M.
  • Tarsus Pharmaceuticals made up 2.54% of Tri Locum Partners's portfolio in Q2 2026, its #14 holding.
  • Tri Locum Partners first reported a position in Tarsus Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Tri Locum Partners's 13F filing for Q2 2026, filed 14 Aug 2026.